TFFP - TFF Pharma plunges 39% after updating timeline for Phase 2 data readouts

• TFF Pharmaceuticals ( NASDAQ: TFFP ), a company focused on inhaled dry powder drugs, dropped ~39% pre-market Wednesday after revising its plans to share early Phase 2 clinical results for lead assets Voriconazole (TFF VORI) and Tacrolimus (TFF TAC).
• Citing issues “related to staffing shortages, shipping, and global supply chain delays,” TFF ( TFFP ) said that preliminary Phase 2 data for the candidate are now expected in Q1 2023 and Q2 2023, respectively.
• While more trial sites are being added to speed up enrollment, the company said that it had addressed the supply chain issues that impacted the purchase of a comparator drug for the TFF VORI trial.
• In a separate press release on Tuesday, TFF ( TFFP ) announced the dosing of the second patient in the compassionate use program for TFF VORI.

For further details see: